Amanta Healthcare’s Rs 126 Crore IPO Closes with Exceptional Demand, Sets Stage for Listing.

Amanta Healthcare’s Rs 126 Crore IPO Closes with Exceptional Demand, Sets Stage for Listing

Amanta Healthcare, a leading sterile liquid pharmaceuticals manufacturer, has just closed its initial public offering (IPO) with an overwhelming market response. The company’s Rs 126 crore IPO was subscribed an astonishing 82.60 times, reflecting strong investor confidence across all categories.

Investor Enthusiasm Across the Board

The IPO subscription revealed remarkable demand from all investor segments. Non-institutional investors led the charge, subscribing 209.42 times their allocated shares. Retail investors, allocated 35% of the issue, showed strong participation with a subscription rate of nearly 55 times. Qualified institutional buyers (QIBs) also demonstrated solid interest, subscribing 35.86 times the shares offered to them.

This broad-based enthusiasm illustrates the faith investors have in Amanta’s business model and growth prospects. Prior to the IPO, the company also secured Rs 37.8 crore from six anchor investors at Rs 126 per share, underscoring institutional confidence.

Moderate Listing Expectations but Positive Outlook

Current grey market premiums indicate a positive but cautious start for Amanta when it lists on the stock exchanges. Shares are trading at a premium of Rs 8.5 to Rs 10 above the IPO price of Rs 126, translating to an expected listing price around Rs 134.5 per share. This represents a decent 6.75-7% listing gain for investors who subscribed at the issue price.

IPO Timeline and Strategic Fund Utilization

Successful bidders will see their share allotments credited to demat accounts by September 8, with the shares officially listed on both the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) on September 9, 2025.

Amanta plans to deploy the IPO proceeds judiciously to fuel growth. Rs 70 crore will finance a new SteriPort manufacturing line at their Gujarat facility in Hariyala, while Rs 30.13 crore will set up a manufacturing line for small volume parenteral products at the same location. The remaining funds are earmarked for general corporate purposes.

Looking Ahead: Amanta’s Growth Story

Founded in 1994, Amanta Healthcare specializes in sterile liquid pharmaceuticals such as intravenous (IV) fluids, diluents, ophthalmic solutions, and respiratory care products. The company currently markets over 45 generic products across India through an extensive network of 320 distributors and exports to 21 countries.

For the year ended March 31, 2025, Amanta reported consolidated sales of Rs 274.71 crore and a net profit of Rs 10.5 crore, reflecting steady financial performance. With the fresh infusion of capital from the IPO, Amanta is well-positioned to expand manufacturing capabilities and deepen market penetration.

In summary, the successful IPO subscription and positive grey market signals suggest a bright future for Amanta Healthcare as it prepares to debut on the stock exchanges. Investors eager to participate can look forward to the shares listing next week and the growth potential that lies ahead.

This milestone marks a significant step for Amanta in its journey towards scaling operations and enhancing shareholder value in the growing pharmaceutical space. Stay tuned for the listing and subsequent market performance updates.